Joyzyme Group Limited (stock name: HUAKANG BIOMED; stock code: 08622) has issued a supplemental announcement to its 29 May 2026 AGM circular, outlining two key points:

1. Auditor Re-appointment • Forvis Mazars CPA Limited, the incumbent auditor, will retire at the forthcoming annual general meeting (AGM) and has offered itself for re-appointment. • The Board, following the Audit Committee’s recommendation, will seek shareholder approval to re-appoint Forvis Mazars for the financial year ending 31 December 2026. • The preliminary audit fee is set in the range of HK$0.75 million to HK$0.83 million. The fee was negotiated at arm’s length and reflects business scale, audit scope, timetable and required resources. Management expects the final fee to remain broadly in line with this range unless material changes arise during the engagement.

2. Share Buy-back Mandate • The company confirmed that the explanatory statement and the proposed share buy-back mandate contain no unusual provisions. • All other details in the original AGM circular remain unchanged.

The Board deems the proposed audit fee fair and in the best interests of both the company and its shareholders. The AGM notice and relevant documents continue to be available on the Hong Kong Stock Exchange website and the company’s official site.